Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.
BACKGROUND: Interleukin (IL)-6 is recognised as an important cytokine involved in inflammatory diseases of the central nervous system (CNS). OBJECTIVE: To perform a large retrospective study designed to test cerebrospinal fluid (CSF) IL-6 levels in the context of neurological diseases, and evaluate...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3754988?pdf=render |
| _version_ | 1818987348560445440 |
|---|---|
| author | Alexandre Wullschleger Viktoria Kapina Nicolas Molnarfi Delphine S Courvoisier Jörg D Seebach Marie-Laure Santiago-Raber Denis F Hochstrasser Patrice H Lalive |
| author_facet | Alexandre Wullschleger Viktoria Kapina Nicolas Molnarfi Delphine S Courvoisier Jörg D Seebach Marie-Laure Santiago-Raber Denis F Hochstrasser Patrice H Lalive |
| author_sort | Alexandre Wullschleger |
| collection | DOAJ |
| description | BACKGROUND: Interleukin (IL)-6 is recognised as an important cytokine involved in inflammatory diseases of the central nervous system (CNS). OBJECTIVE: To perform a large retrospective study designed to test cerebrospinal fluid (CSF) IL-6 levels in the context of neurological diseases, and evaluate its usefulness as a biomarker to help discriminate multiple sclerosis (MS) from other inflammatory neurological diseases (OIND). PATIENTS AND METHODS: We analyzed 374 CSF samples for IL-6 using a quantitative enzyme-linked immunosorbent assay. Groups tested were composed of demyelinating diseases of the CNS (DD, n = 117), including relapsing-remitting MS (RRMS, n = 65), primary progressive MS (PPMS, n = 11), clinically isolated syndrome (CIS, n = 11), optic neuritis (ON, n = 30); idiopathic transverse myelitis (ITM, n = 10); other inflammatory neurological diseases (OIND, n = 35); and non-inflammatory neurological diseases (NIND, n = 212). Differences between groups were analysed using Kruskal-Wallis test and Mann-Whitney U-test. RESULTS: CSF IL-6 levels exceeded the positivity cut-off of 10 pg/ml in 18 (51.4%) of the 35 OIND samples, but in only three (3.9%) of the 76 MS samples collected. CSF IL-6 was negative for all NIND samples tested (0/212). IL-6 cut-off of 10 pg/ml offers 96% sensitivity to exclude MS. CONCLUSION: CSF IL-6 may help to differentiate MS from its major differential diagnosis group, OIND. |
| first_indexed | 2024-12-20T19:05:16Z |
| format | Article |
| id | doaj.art-1a60c10cbe7d47f9832d5982fc251021 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T19:05:16Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1a60c10cbe7d47f9832d5982fc2510212022-12-21T19:29:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7239910.1371/journal.pone.0072399Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.Alexandre WullschlegerViktoria KapinaNicolas MolnarfiDelphine S CourvoisierJörg D SeebachMarie-Laure Santiago-RaberDenis F HochstrasserPatrice H LaliveBACKGROUND: Interleukin (IL)-6 is recognised as an important cytokine involved in inflammatory diseases of the central nervous system (CNS). OBJECTIVE: To perform a large retrospective study designed to test cerebrospinal fluid (CSF) IL-6 levels in the context of neurological diseases, and evaluate its usefulness as a biomarker to help discriminate multiple sclerosis (MS) from other inflammatory neurological diseases (OIND). PATIENTS AND METHODS: We analyzed 374 CSF samples for IL-6 using a quantitative enzyme-linked immunosorbent assay. Groups tested were composed of demyelinating diseases of the CNS (DD, n = 117), including relapsing-remitting MS (RRMS, n = 65), primary progressive MS (PPMS, n = 11), clinically isolated syndrome (CIS, n = 11), optic neuritis (ON, n = 30); idiopathic transverse myelitis (ITM, n = 10); other inflammatory neurological diseases (OIND, n = 35); and non-inflammatory neurological diseases (NIND, n = 212). Differences between groups were analysed using Kruskal-Wallis test and Mann-Whitney U-test. RESULTS: CSF IL-6 levels exceeded the positivity cut-off of 10 pg/ml in 18 (51.4%) of the 35 OIND samples, but in only three (3.9%) of the 76 MS samples collected. CSF IL-6 was negative for all NIND samples tested (0/212). IL-6 cut-off of 10 pg/ml offers 96% sensitivity to exclude MS. CONCLUSION: CSF IL-6 may help to differentiate MS from its major differential diagnosis group, OIND.http://europepmc.org/articles/PMC3754988?pdf=render |
| spellingShingle | Alexandre Wullschleger Viktoria Kapina Nicolas Molnarfi Delphine S Courvoisier Jörg D Seebach Marie-Laure Santiago-Raber Denis F Hochstrasser Patrice H Lalive Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE |
| title | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. |
| title_full | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. |
| title_fullStr | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. |
| title_full_unstemmed | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. |
| title_short | Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. |
| title_sort | cerebrospinal fluid interleukin 6 in central nervous system inflammatory diseases |
| url | http://europepmc.org/articles/PMC3754988?pdf=render |
| work_keys_str_mv | AT alexandrewullschleger cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT viktoriakapina cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT nicolasmolnarfi cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT delphinescourvoisier cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT jorgdseebach cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT marielauresantiagoraber cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT denisfhochstrasser cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases AT patricehlalive cerebrospinalfluidinterleukin6incentralnervoussysteminflammatorydiseases |